Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.3148
- Book/Share 19.5225
- PB 4.333
- Debt/Equity 0.7226
- CurrentRatio 1.4236
- ROIC 0.1828
- MktCap 210999965500.0
- FreeCF/Share 5.8583
- PFCF 14.3323
- PE 12.9395
- Debt/Assets 0.3012
- DivYield 0.0379
- ROE 0.3488
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
Read More
Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:50 AM EDT Company Participants Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Caroline Litchfield - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today for the lunch session. My name is Mohit Bansal.
Read More
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Read More
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Read More
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Read More
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Read More
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
Read More
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Published: August 27, 2025 by: Benzinga
Sentiment: Positive
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.
Read More
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
Published: August 27, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer.
Read More
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
Read More
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Read More
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
Read More
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Neutral
I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular portfolios, offsetting Gardasil weakness and Keytruda patent concerns. The stock offers a solid 4% dividend yield, low PEG ratio, and consistent growth, making it appealing for income and value investors.
Read More
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Read More
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Read More
Why Merck (MRK) is a Top Value Stock for the Long-Term
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
4 Solid Dividend Stocks to Buy On The Cheap
Published: August 05, 2025 by: 24/7 Wall Street
Sentiment: Positive
These 4 dividend stocks have generated steady passive income for investors for many years.
Read More
Income Strategy: I'm Buying 2 Elite Mispriced Dividends
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Positive
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories of capital returns to shareholders. Both appear to be severely mispriced, offering enterprising investors the opportunity to capture value before the market pendulum swings back.
Read More
5 Regular Payout High-Yield VIG Dividends to Outpace the Fed
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
These VIG dividend stocks have high yields and regular payouts. Their yields outpace the Federal Reserve's long-term target.
Read More
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Read More
Merck Stock Is Almost A Classical Benjamin Graham Investment
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Merck is good value for money. It is a highly profitable company. It fulfills almost all of Benjamin Graham's stock-picking criteria.
Read More
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
Read More
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
The Investment Committee debate some of their stocks on the move lower.
Read More
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
Read More
Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Published: July 29, 2025 by: Market Watch
Sentiment: Negative
Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Read More
Merck posts Q2 earnings miss, unveils cost-cutting initiative
Published: July 29, 2025 by: Proactive Investors
Sentiment: Negative
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares moved lower in early trade as the pharmaceutical company reported second quarter earnings that fell short of estimates. Revenue for the quarter came in at $15.8 billion, down 2% year-over-year and below consensus expectations of approximately $15.75 billion.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000